Taiwan
-
China remains one of the fastest growing pharmaceutical markets in the world
China and Japan will be the largest and second largest pharmaceutical markets in the Asia Pacific region in 2016.
Taiwan | 27 April 2012
-
CEL-SCI announces start of Multikine phase 3 study by Orient Europharma in Taiwan
CEL-SCI Corporation announced that its Taiwanese partner, Orient Europharma, has concluded the site initiation visit for the first Taiwanese clinical center in CEL-SCI’s phase 3 clinical trial for Multikine, the company’s flagship cancer immunoth…
Taiwan | 24 June 2011
-
CEL-SCI to commence phase 3 clinical trial of Multikine in Taiwan
CEL-SCI Corporation announced that the Department of Health, Taiwan has issued an approval letter that allows enrollment of patients to begin in Taiwan in the phase 3 clinical trial of Multikine. The approval letter was issued by the Department of He…
Taiwan | 04 May 2011
-
First Taiwanese recipient of SEBM Distinguished Scientist award named
Dr Nan-Shan Chang, Professor and Chair of the Institute of Molecular Medicine at National Cheng Kung University (NCKU), Tainan, Taiwan, is one of the 9 recipients of the 2011 Distinguished Scientist award by the US-based Society for Experimental Biol…
Taiwan | 21 April 2011
-
Increasing incidence of diabetes in Taiwan
The increased incidence of diabetes in Taiwan is driving the growth of self-monitoring of blood glucose (SMBG) devices and strips market in Taiwan. Increasing awareness about the disease to contain and reduce it’s prevalence rate has been the r…
Taiwan | 16 March 2011
-
Pharmacogenomics becomes standard in over 50 hospitals throughout Taiwan
Pharmigene announced a new milestone in the practice of pharmacogenomics and personalized medicine by partnering with over 50 hospitals across Taiwan. According to the company, healthcare providers at these institutions in Taiwan are utilizing Pharmi…
Taiwan | 10 March 2011
-
More Effective and Affordable Hepatitis Therapies Needed in Asia
China, Taiwan and South Korea represent endemic areas for viral hepatitis, with prevalence rates ranging from 4-13 percent for Hepatitis B (HBV) and from 1-4 percent for Hepatitis C (HCV). While there are several therapeutic options available fo…
Taiwan | 20 May 2010
-
Avita Medical to Distribute “Spray-On Skin†in Taiwan
Avita Medical has secured regulatory approval for its ReCell autologous spray-on skin from the Taiwan Ministry of Health. The target market for the product includes plastic and reconstructive surgeons, dermatologists, burns specialists and cosmeti…
Taiwan | 22 April 2010
-
Watson to Divest Ownership in Taiwan Company
Watson Pharmaceuticals has signed an agreement to divest its equity ownership position of approximately 31 percent of ScinoPharm Taiwan. The transaction is subject to the parties obtaining approvals from various government agencies in Taiwan, as …
Taiwan | 18 March 2010
-
Taiwan Awards Companies in Life Science Sector
The "Taiwan Healthcare Industry Innovation and Excellence Awards 2009," recognizing achievements in the local life sciences sector was held in November. "Gold," "Silver" and "Bronze" award winners were chosen from seven companies making a "Commen…
Taiwan | 02 December 2009
